INmune Bio Inc. INMB
Set alert
As of Nov 2, 10:16 AM ET
- YTD
- -6.41%
- 1 year
- -20.22%
- Open
- 1.47
- Prev close
- 1.45
- Mkt cap
- 45.20M
- Vol
- 24.24K
- Avg vol
- 330.77K
- EPS
- -0.67
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.45
- High
- 1.49
- Forward P/E
- -2.23
- Beta
- 1.85
- Short ratio
- 18.08
- Inst. own
- 24.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 1, 2024
- 50-d avg
- 5.27
- 200-d avg
- 7.78
- 1y target
- 19.83
News
4 days ago globenewswire.com
INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, Oct. 29, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology…
5 days ago globenewswire.com
INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement
BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it…
-
1 week ago benzinga.com
INmune Bio Submits Final Pre-Marketing Authorization Application Package To UK MHRA For Ebstrocel For Recessive Dystrophic Epidermolysis Bullosa; Expects Full MAA Submission In Early February 2027, With Potential UK Approval In Mid-2027; Has Engaged U.S. Regulatory Advisors With Rare Disease Expertise To Prepare And Submit A Type B Meeting Request To FDA
INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation…
1 week ago globenewswire.com
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it…
1 week ago globenewswire.com
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) --…
-
2 weeks ago benzinga.com
INmune Bio And Quantum Computing Inc. Partner To Use Quantum AI To Identify New Treatment Applications For Alzheimer’s Drug XPro
Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XProInitial engagement marks…
2 weeks ago prnewswire.com
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™
Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro Initial engagement marks…
3 weeks ago benzinga.com
Full Transcript: INmune Bio Q2 2026 Earnings Call
INmune Bio (NASDAQ:INMB) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…
3 weeks ago globenewswire.com
INmune Bio to Attend the 2026 Maxim Growth Summit
BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its…
1 month ago globenewswire.com
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE…
1 month ago globenewswire.com
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fla, Sept.
2 months ago seekingalpha.com
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment
INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis amid regulatory alignment and a $67M market cap. Ebstrocel offers systemic itch reduction,…
-
2 months ago benzinga.com
INmune Bio Submits Two Regulatory Packages To EMA For Ebstrocel: Application For Orphan Drug Designation And Scientific Advice Package To Streamline Upcoming MAA In Europe
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEBFilings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained…
2 months ago globenewswire.com
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained…
2 months ago seekingalpha.com
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
INmune Bio Q2 Earnings Call Highlights
INmune Bio NASDAQ: INMB outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026,…
3 months ago globenewswire.com
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
BOCA RATON, Fla. , July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that on…
3 months ago globenewswire.com
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology…
3 months ago globenewswire.com
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities
-
3 months ago benzinga.com
INmune Bio Reaches Manufacturing Milestone with First Commercial-Ready CORDStrom Umbilical Cord Tissue Processed At CGT Catapult In Partnership With Anthony Nolan Cord Blood Bank
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply.Company Expresses Support for MHRA Draft Rare…
3 months ago globenewswire.com
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare…
-
3 months ago benzinga.com
INmune Announces Publication Of Peer-Reviewed Study In The Journal Of Neurotrauma On Traumatic Brain Injury And Alzheimer’s; Treatment With Its Lead Neuroinflammation Candidate XPro1595 Prevented Injury-Induced Rise In Amyloid Pathology
The Department of Defense–funded study; entitled: "Inhibition of Soluble TNF Mitigates Traumatic Brain Injury as a Risk Factor for the Development of Amyloidogenic Proteins and Functional Deficits in…
3 months ago globenewswire.com
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
The study points to soluble TNF as a key biological link between head injury and Alzheimer's disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in…
-
3 months ago benzinga.com
INmune Bio To Present New Imaging Data From Phase 2 Study Of XPro In Patients With Early Alzheimer’s Disease At AAIC
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF…
-
4 months ago benzinga.com
INmune Bio Submits Its CORDStrom Platform Patent Application Into The U.S. National Phase Before USPTO
Submission advances a key element of the Company’s global intellectual property strategy for its next-generation mesenchymal stromal cell (MSC) platform.HighlightsAdvanced to U.S. National Phase: The…
-
4 months ago benzinga.com
The UK Medicines & Healthcare Products Regulatory Agency Approves The Pediatric Investigation Plan For INmune Bio's Ebstrocel For Recessive Dystrophic Epidermolysis Bullosa
INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that the UK Medicines & Healthcare products Regulatory Agency…
-
4 months ago benzinga.com
INmune Bio Receives Official Accepted Meeting Minutes From Recent Pre-MAA Scientific Advice Meeting With UK's MHRA For CORDStrom
MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical evidence packages MHRA pediatric feedback recognizes…
7 months ago benzinga.com
Earnings Scheduled For March 30, 2026
Earnings Scheduled For March 30, 2026
1 year ago benzinga.com
Earnings Scheduled For October 30, 2025
Earnings Scheduled For October 30, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
Traders Circulate Business Insider Article Titled "Looking for the short-squeeze candidate? These 5 stocks have potential."; Shares See Volume
https://www.businessinsider.com/short-squeeze-stock-market-meme-stocks-retail-investors-25-8
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
1 year ago benzinga.com
Dow Gains Over 100 Points; Chicago PMI Weakens In June
Dow Gains Over 100 Points; Chicago PMI Weakens In June
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
Why Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket
Why Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
1 year ago benzinga.com
Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
1 year ago benzinga.com
C-Suite Buy of the Week: Executive Moves from Biotech to Banking
C-Suite Buy of the Week: Executive Moves from Biotech to Banking
-
2 years ago benzinga.com
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
-
3 years ago benzinga.com
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.
-
3 years ago benzinga.com
Earnings Scheduled For August 7, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss at $0.44 per share on revenue of $153.69 million.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023
-
3 years ago benzinga.com
Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
-
4 years ago benzinga.com
Earnings Scheduled For November 2, 2022
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.